All In Biotech

Drug Trial Radar · NCT04487080

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,074 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,074

Actual

Start

Sep 30, 2020

Primary completion

Aug 11, 2023

Study completion Feb 16, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • AmivantamabDrug

    Participants will receive amivantamab intravenously.

  • OsimertinibDrug

    Participants will receive osimertinib capsules orally.

  • LazertinibDrug

    Participants will receive lazertinib tablets orally.

  • PlaceboDrug

    Participants will receive matching placebo orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)Time frame: From randomization to either disease progression or death whichever occurs first (up to 32.8 months)

Locations

269 sites in 28 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC - HAL

    Goodyear, Arizona

  • Yuma Regional Medical Center

    Yuma, Arizona

  • City of Hope Long Beach Elm

    Long Beach, California

  • University of California Irvine

    Orange, California

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • University Cancer And Blood Center LLC

    Athens, Georgia

  • East Jefferson General Hospital

    Metairie, Louisiana

  • Maryland Oncology Hematology, PA

    Columbia, Maryland

  • Henry Ford Hospital

    Detroit, Michigan

  • Minnesota Oncology Hematology P A

    Edina, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School Of Medicine

    St Louis, Missouri

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Willamette Valley Cancer Institute and Research Center

    Eugene, Oregon

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Texas Oncology P A

    Austin, Texas

  • Oncology Consultants Texas

    Houston, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Centro Oncológico Korben

    Buenos Aires, Argentina

  • Instituto Alexander Fleming

    Buenos Aires, Argentina

  • Hospital Privado Centro Medico de Cordoba

    Córdoba, Argentina

  • Centro Oncologico Riojano Integral (Cori)

    La Rioja, Argentina

  • Clínica Viedma

    Viedma, Argentina

  • Flinders Medical Centre

    Bedford Park, Australia

  • Austin Hospital

    Heidelberg, Australia

  • Cabrini Medical Centre

    Malvern, Australia

  • St John of God Hospital Murdoch

    Murdoch, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Australia

  • Westmead Hospital

    Westmead, Australia

  • Southern Medical Day Care Centre

    Wollongong, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Australia

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Grand Hopital De Charleroi Site Les Viviers

    Charleroi, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Clinique Saint Pierre

    Ottignies, Belgium

  • Algemeen Ziekenhuis Delta

    Roeselare, Belgium

  • Fundacao Pio XII

    Barretos, Brazil

  • Cetus Oncologia

    Belo Horizonte, Brazil

Showing 40 of 269 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.